pFIB scores for paediatric MASLD fibrosis are associated with risk of youth-onset type 2 diabetes in children with obesity
Diabetologia · 2026
DOI: 10.1007/s00125-026-06804-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologia, 2026. Verfasst von Sander Lefere und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology Research Unit, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Liver Cirrhosis, Pediatric Obesity, Fatty Liver. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Center for Innovative Medicine, Fonds Wetenschappelijk Onderzoek.
Themen: Diabetes mellitus, Kinderkrankenpflege
Abstract (Originalsprache)
Aims/hypothesis Youth-onset type 2 diabetes is an aggressive phenotype of metabolic disease, yet tools to identify children with obesity at highest short-term risk are limited. We evaluated whether the paediatric liver fibrosis risk scores (pFIB) pFIB-c and pFIB-6, originally developed for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk stratification, identify individuals at increased risk of incident type 2 diabetes.
Methods
A cohort study was conducted using the Swedish Childhood Obesity Treatment Register (BORIS, 2005–2020) linked with national registers, from which type 2 diabetes was ascertained. We included 4856 children with obesity (aged 12.0 years at baseline) and 23,758 general population comparators. The pFIB-c and pFIB-6 scores were calculated as published. Time-to-event analysis yielding HR was performed using Cox regression and flexible parametric survival models.
Results
Among children with obesity, 12.4% had a pFIB-6 ≥4. A high pFIB-6 score increased the risk for type 2 diabetes at 9–19 years of age (adjusted HR 3.05 [95% CI 2.17, 4.28]). The incidence rate (95% CI) per 10,000 person-years was 1.02 (0.61, 1.72) in the general population comparators, 45.5 (37.8, 54.7) in individuals with obesity and a pFIB-6
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hepatology Research Unit, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
- Liver Research Center Ghent, Ghent University Hospital, Ghent, Belgium.
- Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Hepatology Research Unit, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium. ruth.debruyne@uzgent.be.
Förderung
- Deutsche Forschungsgemeinschaft
- Center for Innovative Medicine
- Fonds Wetenschappelijk Onderzoek
- Karolinska Institute
Zitieren
APA
Lefere, S., Putri, R. R., Danielsson, P., Casswall, T., Marcus, C., Hudert, C. A., Geerts, A., De Bruyne, R., & Hagman, E. (2026). pFIB scores for paediatric MASLD fibrosis are associated with risk of youth-onset type 2 diabetes in children with obesity. Diabetologia. https://doi.org/10.1007/s00125-026-06804-4
Vancouver
Lefere S, Putri RR, Danielsson P, Casswall T, Marcus C, Hudert CA, et al. pFIB scores for paediatric MASLD fibrosis are associated with risk of youth-onset type 2 diabetes in children with obesity. Diabetologia. 2026. doi:10.1007/s00125-026-06804-4
BibTeX
@article{Lefere2026,
author = {Lefere, Sander and Putri, Resthie R and Danielsson, Pernilla and Casswall, Thomas and Marcus, Claude and Hudert, Christian A and Geerts, Anja and De Bruyne, Ruth and Hagman, Emilia},
title = {pFIB scores for paediatric MASLD fibrosis are associated with risk of youth-onset type 2 diabetes in children with obesity},
journal = {Diabetologia},
year = {2026},
doi = {10.1007/s00125-026-06804-4}
}
EUVIMED